Neurotensin agonists: Possible drugs for treatment of psychostimulant abuse

Life Sciences

Volumn 73, Issue 6, 2003, Pages 679-690

  Richelson, Elliott ^a   Boules, Mona ^a   Fredrickson, Paul ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; 2 [[1 (7 CHLORO 4 QUINOLINYL) 5 (2,6 DIMETHOXYPHENYL) 3 PYRAZOLYL]CARBONYLAMINO] 2 ADAMANTANECARBOXYLIC ACID; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; LEVOCABASTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR ANTAGONIST; NT 69L; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTINOCICEPTION; CATALEPSY; CONFERENCE PAPER; DRUG DEPENDENCE; DRUG SENSITIZATION; HYPOTENSION; HYPOTHERMIA; MESOLIMBIC DOPAMINERGIC SYSTEM; MOLECULAR CLONING; NONHUMAN; SEDATION; SUBSTANTIA NIGRA; TARDIVE DYSKINESIA;

EID: 0037498436     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(03)00388-6     Document Type: Conference Paper

References (96)

1. Adams D.H., Hanson G.R., Keefe K.A. Differential effects of cocaine and methamphetamine on neurotensin/neuromedin N and preprotachykinin messenger RNA expression in unique regions of the striatum. Neuroscience. 102(4):2001;843-851.
2. Al-Rodhan N.R., Richelson E., Gilbert J.A., McCormick D.J., Kanba K.S., Pfenning M.A., Nelson A., Larson E.W., Yaksh T.L. Structure-antinociceptive activity of neurotensin and some novel analogues in the periaqueductal gray region of the brainstem. Brain Research. 557(1-2):1991;227-235.
3. 3H]levocabastine. Neuroreport. 12(5):2001;1087-1091.
4. Bauco P., Rompre P.P. Effects of neurotensin receptor activation on brain stimulation reward in Fischer 344 and Lewis rats. European Journal of Pharmacology. 432(1):2001;57-61.
5. Beaudet A., Mazella J., Nouel D., Chabry J., Castel M.N., Laduron P., Kitabgi P., Faure M.P. Internalization and intracellular mobilization of neurotensin in neuronal cells. Biochemical Pharmacology. 47(1):1994;43-52.
6. Betancur C., Cabrera R., deKloet R., Pelaprat D., Rostene W. Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Neuropsychopharmacology. 19(4):1998;322-332.
7. Betancur C., Rostene W., Berod A. Chronic cocaine increases neurotensin gene expression in the shell of the nucleus accumbens and in discrete regions of the striatum. Molecular Brain Research. 44:1997;334-340.
8. Bissette G., Nemeroff C.B., Loosen P.T., Prange A.J. Jr., Lipton M.A. Hypothermia and intolerance to cold induced by intracisternal administration of the hypothalamic peptide neurotensin. Nature. 262(5569):1976;607-609.
9. Boudin H., Pelaprat D., Rostene W., Beaudet A. Cellular distribution of neurotensin receptors in rat brain: Immunohistochemical study using an antipeptide antibody against the cloned high affinity receptor. Journal of Comparative Neurology. 373(1):1996;76-89.
10. Boules M., Cusack B., Zhao L.H., Fauq A., McCormick D.J., Richelson E. A novel neurotensin peptide analog given extracranially decreases food intake and weight in rodents. Brain Research. 865(1):2000;35-44.
11. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. Antiparkinson-like effects of a novel neurotensin analog in unilaterally 6-hydroxydopamine lesioned rats. European Journal of Pharmacology. 428(2):2001;227-233.
12. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. A novel neurotensin analog blocks cocaine-and D-amphetamine-induced hyperactivity. European Journal of Pharmacology. 426(1-2):2001;73-76.
13. Burgevin M.C., Castel M.N., Quarteronet D., Chevet T., Laduron P.M. Neurotensin increases tyrosine hydroxylase messenger RNA-positive neurons in substantia-nigra after retrograde axonal transport. Neuroscience. 49(3):1992;627-633.
14. Cain S.T., Griff D., Joyner C.M., Ellinwood E.H., Nemeroff C.B. Chronic continuous or intermittent infusion of cocaine differentially alter the concentration of neurotensin-like immunoreactivity in specific rat brain regions. Neuropsychopharmacology. 8(3):1993;259-265.
15. Carraway R., Leeman S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. Journal of Biological Chemistry. 248:1973;6854-6861.
16. Castel M.N., Malgouris C., Blanchard J.C., Laduron P.M. Retrograde axonal transport of neurotensin in the rat brain. European Journal of Pharmacology. 166:1989;353-354.
17. Castel M.N., Malgouris C., Blanchard J.C., Laduron P.M. Retrograde axonal transport of neurotensin in the dopaminergic nigrostriatal pathway in the rat. Neuroscience. 36:1990;425-430.
18. Castel M.N., Morino P., Dagerlind A., Hokfelt T. Up-regulation of neurotensin mRNA in the rat striatum after acute methamphetamine treatment. European Journal of Neuroscience. 6(4):1994;646-656.
19. Castel M.N., Morino P., Frey P., Terenius L., Hokfelt T. Immunohistochemical evidence for a neurotensin striatonigral pathway in the rat brain. Neuroscience. 55(3):1993;833-847.
20. Castel M.N., Woulfe J., Wang X., Laduron P.M., Beaudet A. Light and electron microscopic localization of retrogradely transported neurotensin in rat nigrostriatal dopaminergic neurons. Neuroscience. 50(2):1992;269-282.
21. Chalon P., Vita N., Kaghad M., Guillemot M., Bonnin J., Delpech B., LeFur G., Ferrara P., Caput D. Molecular cloning of a levocabastine-sensitive neurotensin binding site. FEBS Letters. 386(2-3):1996;91-94.
22. Clineschmidt B.V., McGuffin J.C. Neurotensin administered intracisternally inhibits responsiveness of mice to noxious stimuli. European Journal of Pharmacology. 46(4):1977;395-396.
23. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D.J., Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Research. 856(1-2):2000;48-54.
24. Cusack B., Chou T., Jansen K., McCormick D.J., Richelson E. Analysis of binding sites and efficacy of a species-specific peptide at rat and human neurotensin receptors. Journal of Peptide Research. 55(1):2000;72-80.
25. Cusack B., Groshan K., McCormick D.J., Pang Y.P., Perry R., Phung C.T., Souder T., Richelson E. Chimeric rat/human neurotensin receptors localize a region of the receptor sensitive to binding of a novel, species-specific, picomolar affinity peptide. Journal of Biological Chemistry. 271(25):1996;15054-15059.
26. Cusack B., McCormick D.J., Pang Y.P., Souder T., Garcia R., Fauq A., Richelson E. Pharmacological and biochemical profiles of unique neurotensin 8-13 analogs exhibiting species selectivity, stereoselectivity, and superagonism. Journal of Biological Chemistry. 270(31):1995;18359-18366.
27. Cusack B., Richelson E., Pang Y.P., Zaidi J., Kozikowski A.P. Pharmacological studies on novel neurotensin mimetics: discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist. Molecular Pharmacology. 44(5):1993;1036-1040.
28. DiazCabiale Z., Fuxe K., Narvaez J.A., Finetti S., Antonelli T., Tanganelli S., Ferraro L. Neurotensin-induced modulation of dopamine D2 receptors and their function in rat striatum: Counteraction by a NTRI-like receptor antagonist. Neuroreport. 13(6):2002;763-766.
29. DiChiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. European Journal of Pharmacology. 393:2000;295-314.
30. Dobner P.R., Fadel J., Deitemeyer N., Carraway R.E., Deutch A.Y. Neurotensin-deficient mice show altered responses to antipsychotic drugs. Proceedings of the National Academy of Sciences USA. 98(14):2001;8048-8053.
31. Dodd D.S., Kozikowski A.P., Cusack C., Richelson E. Synthesis of partially non-peptidic neurotensin mimetics. Bioorganic and Medicinal Chemistry Letters. 4:1994;1241-1246.
32. Drumheller A.D., Gagne M.A., St-Pierre S., Jolicoeur F.B. Effects of neurotensin on regional brain concentrations of dopamine, serotonin and their main metabolites. Neuropeptides. 15(3):1990;169-178.
33. Ervin G.N., Birkemo L.S., Nemeroff C.B., Prange A.J. Jr. Neurotensin blocks certain amphetamine-induced behaviours. Nature. 291(5810):1981;73-76.
34. Fauq A.H., Hong F., Cusack B., Tyler B.M., Pang Y.-P., Richelson E. Synthesis of (2S)-2-amino-3-(1H-4-indolyl)propanoic acid, a novel tryptophan analog for structural modification of bioactive peptides. Tetrahedron: Asymmetry. 9(23):1998;4127-4134.
35. 11-neurotensin on mesolimbic and nigrostriatal dopaminergic function in the rat. Brain Research. 534(1-2):1990;243-250.
36. Fredrickson P., Boules M., Yerbury S., Richelson E. Novel neurotensin analog blocks the initiation and expression od sensitization to nicotine. Brain Research. 2003;. in press.
37. Glimcher P.W., Giovino A.A., Hoebel B.G. Neurotensin self-injection in the ventral tegmental area. Brain Research. 403(1):1987;147-150.
38. Glimcher P.W., Margolin D.H., Giovino A.A., Hoebel B.G. Neurotensin: a new 'reward peptide'. Brain Research. 291(1):1984;119-124.
39. Govoni S., Hong J.S., Yang H.Y., Costa E. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics. 215:1980;413-417.
40. Gully D., Canton M., Boigegrain R., Jeanjean F., Molimard J.C., Poncelet M., Gueudet C., Heaulme M., Leyris R., Brouard A., Pelaprat D., Labbejullie C., Mazella J., Soubrie P., Maffrand J.P., Rostene W., Kitabgi P., Lefur G. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proceedings of the National Academy of Sciences USA. 90(1):1993;65-69.
41. Gully D., Labeeuw B., Boigegrain R., Oury-Donat F., Bachy A., Poncelet M., Steinberg R., Suaud-Chagny M.F., Santucci V., Vita N., Pecceu F., Labbe-Jullie C., Kitabgi P., Soubrie P., Le Fur G., Maffrand J.P. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. Journal of Pharmacology and Experimental Therapeutics. 280(2):1997;802-812.
42. Gygi S.P., Gibb J.W., Hanson G.R. Differential effects of antipsychotic and psychotomimetic drugs on neurotensin systems of discrete extrapyramidal and limbic regions. Journal of Pharmacology and Experimental Therapeutics. 270(1):1994;192-197.
43. Hahn B., Stolerman I.P., Shoaib M. Kappa-opioid receptor modulation of nicotine-induced behaviour. Neuropharmacology. 39(13):2000;2848-2855.
44. Hanson G.R., Singh N., Merchant K., Johnson M., Gibb J.W. The role of NMDA receptor systems in neuropeptide responses to stimulants of abuse. Drug and Alcohol Dependence. 37(2):1995;107-110.
45. Hertel P., Olsen C.K., Arnt J. Repeated administration of the neurotensin analogue NT69L induces tolerance to its suppressant effect on conditioned avoidance behaviour. European Journal of Pharmacology. 439(1-3):2002;107-111.
46. Hong F., Pang Y.P., Cusack B., Richelson E. Design, synthesis and pharmacological test of a quinoline based, nonpeptidic analogue of neurotensin(8-13). Journal of the Chemical Society Perkin Transactions. 1(14):1997;2083-2088.
47. Hong F., Zaidi J., Pang Y.P., Cusack B., Richelson E. Design, synthesis and pharmacological evaluation of active pyrrole based, nonpeptidic analogues of neurotensin(8-13). Journal of the Chemical Society Perkin Transactions. 1(20):1997;2997-3003.
48. Horger B.A., Taylor J.R., Elsworth J.D., Roth R.H. Preexposure to, but not cotreatment with, the neurotensin antagonist SR 48692 delays the development of cocaine sensitization. Neuropsychopharmacology. 11(3):1994;215-222.
49. Jolicoeur F.B., Gagne M.A., Rivest R., Drumheller A., Stpierre S. Atypical neuroleptic-like behavioral effects of neurotensin. Brain Research Bulletin. 32(5):1993;487-491.
50. Kalivas P.W. Blockade of neurotensin-induced motor activity by inhibition protein kinase. Psychopharmacology. 114(1):1994;175-180.
51. Kalivas P.W., Duffy P. Effect of acute and daily cocaine treatment on extracellular dopamine in the nucleus accumbens. Synapse. 5(1):1990;48-58.
52. Kalivas P.W., Duffy P. Effect of acute and daily neurotensin and enkephalin treatments on extracellular dopamine in the nucleus accumbens. Journal of Neuroscience. 10(9):1990;2940-2949.
53. Kalivas P.W., Taylor S. Behavioral and neurochemical effect of daily injection with neurotensin into the ventral tegmental area. Brain Research. 358:1985;70-76.
54. Kitabgi P., Carraway R., Van Rietschoten J., Granier C., Morgat J.L., Menez A., Leeman S., Freychet P. Neurotensin: specific binding to synaptic membranes from rat brain. Proceedings of the National Academy of Sciences USA. 74(5):1977;1846-1850.
55. Kitabgi P., Rostene W., Dussaillant M., Schotte A., Laduron P.M., Vincent J.P. Two populations of neurotensin binding sites in murine brain: discrimination by the antihistamine levocabastine reveals markedly different radioautographic distribution. European Journal of Pharmacology. 140(3):1987;285-293.
56. Lahti R.A., Cochrane E.V., Roberts R.C., Conley R.R., Tamminga C.A. [H-3]Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons. An autoradiographic study. Journal of Neural Transmission. 105(4-5):1998;507-516.
57. Le F., Cusack B., Richelson E. The neurotensin receptor: is there more than one subtype? Trends in Pharmacological Sciences. 17(1):1996;1-3.
58. Mazella J., Botto J.M., Guillemare E., Coppola T., Sarret P., Vincent J.P. Structure, functional expression, and cerebral localization of the levocabastine-sensitive neurotensin/neuromedin N receptor from mouse brain. Journal of Neuroscience. 16(18):1996;5613-5620.
59. Mazella J., Zsurger N., Navarro V., Chabry J., Kaghad M., Caput D., Ferrara P., Vita N., Gully D., Maffrand J.P., Vincent J.P. The 100-kDa neurotensin receptor is gp95/sortilin, a non-G-protein-coupled receptor. Journal of Biological Chemistry. 273(41):1998;26273-26276.
60. McBride W.J., Murphy J.M., Ikemoto S. Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behavioral Brain Research. 101(2):1999;129-152.
61. Merchant K.M., Dobner P.R., Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. Journal of Neuroscience. 12(2):1992;652-663.
62. Merchant K.M., Dorsa D.M. Differential induction of neurotensin and c-fos gene expression by typical versus atypical antipsychotics. Proceedings of the National Academy of Sciences USA. 90(8):1993;3447-3451.
63. Merchant K.M., Hanson G.R., Dorsa D.M. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: Comparison with acute haloperidol effects. Journal of Pharmacology and Experimental Therapeutics. 269(2):1994;806-812.
64. Munkvad I., Pakkenberg H., Randrup A. Aminergic systems in the basal ganglia associated with stereotyped behavior and catalepsy. Brain, Behavior, and Evolution. 1:1968;89-100.
65. Najimi M., Hermans E., Rostene W., Forgez P. Transcriptional regulation of the tyrosine hydroxylase gene by neurotensin in human neuroblastoma CHP212 cells. Metabolic Brain Disease. 16(3-4):2001;165-174.
66. Nemeroff C.B. Neurotensin: perchance an endogenous neuroleptic? Biological Psychiatry. 15(2):1980;283-302.
67. Nemeroff C.B., Luttinger D., Hernandez D.E., Mailman R.B., Mason G.A., Davis S.D., Widerlov E., Frye G.D., Kilts C.A., Beaumont K., Breese G.R., Prange A.J. Jr. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies. Journal of Pharmacology and Experimental Therapeutics. 225(2):1983;337-345.
68. Nemeroff C.B., Osbahr A.J. III, Manberg P.J., Ervin G.N., Prange A.J. Jr. Alterations in nociception and body temperature after intracisternal administration of neurotensin, beta-endorphin, other endogenous peptides, and morphine. Proceedings of the National Academy of Sciences USA. 76(10):1979;5368-5371.
69. Panayi F., Dorso E., Lambas-Senas L., Renaud B., Scarna H., Berod A. Chronic Blockade of Neurotensin Receptors Strongly Reduces Sensitized, but Not Acute, Behavioral Response to D-amphetamine. Neuropsychopharmacology. 26(1):2002;64-74.
70. Pang Y.P., Cusack B., Groshan K., Richelson E. Proposed ligand binding site of the transmembrane receptor for neurotensin(8-13). Journal of Biological Chemistry. 271(25):1996;15060-15068.
71. Pettibone D.J., Hess J.F., Hey P.J., Jacobson M.A., Leviten M., Lis E.V., Mallorga P.J., Pascarella D.M., Snyder M.A., Williams J.B., Zeng Z. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. Journal of Pharmacology and Experimental Therapeutics. 300(1):2002;305-313.
72. Pierce R.C., Kalivas P.W. A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Research Reviews. 25(2):1997;192-216.
73. Pilotte N.S., Mitchell W.M., Sharpe L.G., De Souza E.B., Dax E.M. Chronic cocaine administration and withdrawal of cocaine modify neurotensin binding in rat brain. Synapse. 9(2):1991;111-120.
74. Roberts D.C., Corcoran M.E., Fibiger H.C. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacology, Biochemistry, and Behavior. 6(6):1977;615-620.
75. Roberts D.C., Koob G.F., Klonoff P., Fibiger H.C. Extinction and recovery of cocaine self-administration following 6-hydroxydopamine lesions of the nucleus accumbens. Pharmacology, Biochemistry, and Behavior. 12(5):1980;781-787.
76. Robledo P., Maldonado R., Koob G.F. Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat. Brain Research. 622(1-2):1993;105-112.
77. Rompre P.P., Perron S. Evidence for a role of endogenous neurotensin in the initiation of amphetamine sensitization. Neuropharmacology. 39(10):2000;1880-1892.
78. Schotte A., Leysen J.E., Laduron P.M. Evidence for a displaceable non-specific [3H]neurotensin binding site in rat brain. Naunyn Schmiedebergs Arch Pharmacol. 333(4):1986;400-405.
79. Schotte A., Rostene W., Laduron P.M. Different subcellular localization of neurotensin-receptor and neurotensin-acceptor sites in the rat brain dopaminergic system. Journal of Neurochemistry. 50:1988;1026-1031.
80. Sharma R.P., Janicak P.G., Bissette G., Nemeroff C.B. CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder. American Journal of Psychiatry. 154(7):1997;1019-1021.
81. Studler J.M., Kitabgi P., Tramu G., Herve D., Glowinski J., Tassin J.P. Extensive co-localization of neurotensin with dopamine in rat meso-cortico-frontal dopaminergic neurons. Neuropeptides. 11:1988;95-100.
82. Tanaka K., Masu M., Nakanishi S. Structure and functional expression of the cloned rat neurotensin receptor. Neuron. 4:1990;847-854.
83. Tyler B.M., Cusack B., Douglas C.L., Souder T., Richelson E. Evidence for additional neurotensin receptor subtypes: neurotensin analogs that distinguish between neurotensin-mediated hypothermia and antinociception. Brain Research. 792(2):1998;246-252.
84. Tyler B.M., Douglas C.L., Fauq A., Pang Y.P., Stewart J.A., Cusack B., McCormick D.J., Richelson E. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood-brain barrier. Neuropharmacology. 38(7):1999;1027-1034.
85. Tyler B.M., Jansen K., McCormick D.J., Douglas C.L., Boules M., Stewart J.A., Zhao L., Lacy B., Cusack B., Fauq A., Richelson E. Peptide nucleic acids targeted to the neurotensin receptor and administered i.p. cross the blood-brain barrier and specifically reduce gene expression. Proceedings of the National Academy of Sciences USA. 96(12):1999;7053-7058.
86. Tyler-McMahon B.M., Boules M., Richelson E. Neurotensin: peptide for the next millennium. Regulatory Peptides. 93(1-3):2000;125-136.
87. Tyler-McMahon B.M., Stewart J.A., Farinas F., McCormick D.J., Richelson E. Highly potent neurotensin analog that causes hypothermia and antinociception. European Journal of Pharmacology. 390(1-2):2000;107-111.
88. Uhl G.R., Snyder S.H. Neurotensin receptor binding, regional and subcellular distributions favor transmitter role. European Journal of Pharmacology. 41(1):1977;89-91.
89. Vincent J.P., Mazella J., Kitabgi P. Neurotensin and neurotensin receptors. Trends in Pharmacological Sciences. 20(7):1999;302-309.
90. Vita N., Chalon P., Donat F., Bachy A., Kaghad M., Guillemot M., Thurneyssen O., Bonnin J., Delpech B., Soubrié P., Le Fur G., Caput D., Ferrara P. Molecular cloning and characterization of a new human neurotensin binding site that recognizes levocabastine [abstract]. Society for Neuroscience. 23:1997;394.
91. Vita N., Laurent P., Lefort S., Chalon P., Dumont X., Kaghad M., Gully D., Lefur G., Ferrara P., Caput D. Cloning and expression of a complementary DNA encoding a high affinity human neurotensin receptor. FEBS Letters. 317(1-2):1993;139-142.
92. Vita N., OuryDonat F., Chalon P., Guillemot M., Kaghad M., Bachy A., Thurneyssen O., Garcia S., PoinotChazel C., Casellas P., Keane P., LeFur G., Maffrand J.P., Soubrie P., Caput D., Ferrara P. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. European Journal of Pharmacology. 360(2-3):1998;265-272.
93. Wagstaff J.D., Gibb J.W., Hanson G.R. Microdialysis assessment of methamphetamine-induced changes in extracellular neurotensin in the striatum and nucleus accumbens. Journal of Pharmacology and Experimental Therapeutics. 278(2):1996;547-554.
94. Walker N., Lepee-Lorgeoux I., Fournier J., Betancur C., Rostene W., Ferrara P., Caput D. Tissue distribution and cellular localization of the levocabastine-sensitive neurotensin receptor mRNA in adult rat brain. Molecular Brain Research. 57:1998;193-200.
95. Watson M., Isackson P.J., Makker M., Yamada M.S., Yamada M., Cusack B., Richelson E. Identification of a polymorphism in the human neurotensin receptor gene. Mayo Clinic Proceedings. 68(11):1993;1043-1048.
96. Wolf S.S., Hyde T.M., Saunders R.C., Herman M.M., Weinberger D.R., Kleinman J.E. Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects. Journal of Neural Transmission. 102(1):1995;55-65.